Bedford, Mass., USA - Hologic, a developer of diagnostic products, announced that David R. LaVance, Jr. has resigned as chairman and will not stand for re-election at the 2016 AGM.
Article continues below
Mr. LaVance has been one of directors since December 2002.
He served as Lead Independent Director from June 2008 until July 2011, and as Chairman of the Board from July 2011 to June 2015.
Since June 2011, Mr. LaVance has served as the Chairman of the Board of Directors, CEO and President of Integrated Environmental Technologies.
Since 2003, he has served as the Chairman of the Board of Directors, CEO and President of Scivanta Medical Corporation.
Since 1997, Mr. LaVance has served as President of Century Capital Associates.
Steve MacMillan, Hologic's President and Chief Executive Officer, has been appointed Chairman of the Board.
Mr. MacMillan joined Hologic in December 2013 as President and CEO, and has led a dramatic turnaround at the Company.
He was appointed Chairman of the Board of Directors in June 2015.
From 2005 to 2012, Mr. MacMillan served as President and Chief Executive Officer of Stryker Corporation, where he had been President since 2003.
Prior to 2003, he was a senior executive with Pharmacia Corporation.
He spent 11 years with Johnson & Johnson in a variety of senior roles both in the U.S. and Europe, including President of the joint venture between Johnson & Johnson and Merck.
Mr. MacMillan began his career with Procter and Gamble in 1985.
He received a Bachelor of Arts degree in Economics from Davidson College and is a graduate of Harvard Business School’s Advanced Management Program.
Mr. MacMillan currently serves on the board of directors of Boston Scientific Corp and AdvaMed, the industry association for the medical technology industry.
He previously served on the Boards of Directors of Alere, Inc. and Texas Instruments.
Director Elaine S. Ullian has been appointed Lead Independent Director.
Ms. Ullian has been a member of the Company's Board since 2007.
She served as President and Chief Executive Officer of Boston Medical Center, the successor of Boston University Medical Center Hospital from 1996 until her retirement in January 2010.
In April 1994, Ms. Ullian was appointed President and Chief Executive Officer of Boston University Medical Center Hospital.
From January 1987 to March 1994, she held the position of President and Chief Executive Officer of Faulkner Corporation/Faulkner Hospital.
She holds two academic appointments: Associate Professor at Boston University School of Medicine and lecturer at Harvard University School of Public Health
Ms. Ullian also serves as a director of Vertex Pharmaceuticals Incorporated and Thermo Fisher Scientific.
She previously served as one of the company's directors from 1996 to 2003 and served as a director of Valeant Pharmaceuticals International from 2004 to 2008. ■